1. Van Damme, Helena, Dombrecht, Bruno, Kiss, Máté, Laoui, Damya, Van Ginderachter, Jo Agnes. . Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. In Journal for immunotherapy of cancer, 9, . doi:10.1136/jitc-2020-001749. https://pubmed.ncbi.nlm.nih.gov/33589525/
2. Campbell, Joseph R, McDonald, Bryan R, Mesko, Paul B, Jain, Renu, Lan, Ruth Y. 2021. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. In Cancer research, 81, 2983-2994. doi:10.1158/0008-5472.CAN-20-3585. https://pubmed.ncbi.nlm.nih.gov/33757978/
3. Kidani, Yujiro, Nogami, Wataru, Yasumizu, Yoshiaki, Ohkura, Naganari, Sakaguchi, Shimon. . CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. In Proceedings of the National Academy of Sciences of the United States of America, 119, . doi:10.1073/pnas.2114282119. https://pubmed.ncbi.nlm.nih.gov/35140181/
4. Luo, Yikai, Xia, Yu, Liu, Dan, Liang, Han, Gao, Qinglei. 2024. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. In Cell, 187, 4905-4925.e24. doi:10.1016/j.cell.2024.06.013. https://pubmed.ncbi.nlm.nih.gov/38971151/
5. Liu, Shuna, Tao, Ziqi, Lou, Jianfang, Mao, Yepeng, Wang, Fang. 2023. CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation. In Journal of translational medicine, 21, 803. doi:10.1186/s12967-023-04686-3. https://pubmed.ncbi.nlm.nih.gov/37950246/
6. Chen, Qian, Shen, Meiying, Yan, Min, Hu, Chao, Jin, Aishun. 2024. Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer. In Journal of translational medicine, 22, 709. doi:10.1186/s12967-024-05518-8. https://pubmed.ncbi.nlm.nih.gov/39080766/
智鼠故事 
